A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS

  1. What does it mean when a company in the drug sector has orphan drugs?

    Understand what it means when a company in the pharmaceutical industry has drugs within its portfolio that are designated ...
  2. Are so-called self-offering and self-management covered by "Financial Instruments ...

    Learn a little bit about the regulation of Japanese securities, particularly as it pertains to self-offering for investments ...
  3. How did the Dodd-Frank Act change whistleblower protection and processes?

    Learn how the Dodd-Frank Act changed whistleblower protection and processes by establishing a bounty program and expanding ...
  4. What is the minimum capital adequacy ratio that must be attained under Basel III?

    Find out more about the capital adequacy ratio, or CAR, and the minimum capital adequacy ratio that banks must attain under ...
RELATED TERMS
  1. Structured Transaction

    A series of transactions that could have been treated as a single ...
  2. The New Deal

    A series of domestic programs designed to help the United States ...
  3. Assigned Risk

    A risk that an insurance company is required to provide coverage ...
  4. NEXUS

    A Trusted Traveler Program that allows pre-screened U.S. and ...
  5. Global Entry

    A U.S. program giving pre-approved travelers a faster Customs ...
  6. SENTRI

    This U.S. program grants pre-approved travelers access to a faster ...

You May Also Like

Related Articles
  1. Investing Basics

    What does it mean when a company in ...

  2. Fundamental Analysis

    Is Baidu a Real Threat to Google?

  3. Economics

    The Economics Of Solar Power

  4. Investing Basics

    Google's Take On The Net Neutrality ...

  5. Taxes

    Corporate Tax Rates: The Highs and the ...

Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!